

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: CAMPBELL, Gordon Iain

Serial No.: 10/577841

Confirmation No.: 6066

International Filing Date: October 28, 2004

Group Art Unit: 1626

US Nat'l Entry

Examiner:

Date (if applicable): April 28, 2006

Rebecca L Anderson

For: MORPHOLINE DERIVATIVES AS NOREPINEPHRINE
REUPTAKE INHIBITORS

Docket No.: X15830

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97(c), Applicants submit a Form PTO-1449 (modified) for consideration by the Examiner. Because the cited document is a US patent publication, no copy is provided.

Since this Statement is being filed after the period specified in §1.97(b), but before the mailing date of a final action or a notice of allowance, under §1.97(e)(2), I state no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement.

The cited document US 7,354,920 was granted on April 8, 2008; and is the US national stage of the previously cited International Application WO 2004/018441.

Applicants request consideration of this information.

Respectfully submitted,

/Thomas E. Jackson/

Thomas E. Jackson
Attorney for Applicant(s)/Assignee
Registration No. 33,064
Phone: 317-277-3735

Eli Lilly and Company
Patent Division/TEJ
P.O. Box 6288
Indianapolis, Indiana 46206-6288

June 3, 2008